Browse by Tags

• Yahoo's stock: Back to pre-Microsoft levels

  Posted Aug 22 2008, 01:37 AM by Charley Blaine
  Filed under: Investing, Google, Microsoft, Yahoo
  Rating:

  

  Here's something the top management of Yahoo may wish nobody noticed.

  The stock is now lower than its $19.18 close on Jan. 31, the day before Microsoft launched its $33-a-share, $44.6 billion offer for the Internet company. (Microsoft is the publisher of MSN Money.)

  Yahoo closed Thursday at $19.11. On Wednesday, it closed at $19.17.

  While Yahoo can say it fought off Microsoft and a potential proxy fight from activist Carl Icahn, the victory has been costly. And not just because the company spent $36 million waging the fight   Read More...

  Discuss ( 9 comments) 7,799 Views Digg this | Email this | Link to this

• Will one man decide if Microsoft wins Yahoo?

  Posted Feb 11 2008, 08:30 PM by Charley Blaine
  Filed under: Investing, Google, Microsoft, Yahoo, stocks
  Rating:

  

  Chances are you haven't heard of Gordon Crawford, but my guess is that both Microsoft and Yahoo are paying close attention to whatever he thinks of Microsoft's $44.6 billion bid for Yahoo. (Microsoft is the publisher of MSN Money)

  Crawford is a senior vice president at Capital Research and Management, the nation's largest mutual fund company. For years, he has been one of the world's top players in media investing. He helped Ted Turner sell Turner Broadcasting to Time Warner. Turner and Crawford are still pals; they share a passion for fly fishing.

  And Crawford was one of the people who engineered Steve Case's departure from the board of Time Warner, back in those unhappy days when the media giant was AOL-Time Warner.

  More important for our discussion: Capital Research is Yahoo's largest shareholder with 11.6% of the outstanding shares -- nearly twice as many as Yahoo co-founder David Filo. Capital Research boosted its position in Yahoo by 49.4% in the third quarter and, according to The Wall Street Journal, increased its stake in the fourth quarter.   Read More...

  Discuss ( 12 comments) 25,360 Views Digg this | Email this | Link to this

• Gilead: A drug habit worth having

  Posted Nov 06 2007, 04:53 AM by Jon Markman
  Filed under: Investing, Google, Microsoft, Apple, Trading
  Rating:

  

  When you think about the surprising success of the Nasdaq 100 index this year, the first things that naturally come to mind are tech powerhouses like Google, Apple and Microsoft. But you’ve got a leave a little room for the love of biotech too, and my favorite name there is Gilead Sciences.

  The immunology specialist has really proven immune to selling for most of its life in the public arena, as it is one of the most successful stocks of any type of the past 10 years, with 2,075% capital appreciation stemming from steadfast invention and marketing of biotech therapies.
  
  Pushing shares to a new high in the past week, though, were positive vibes at the 58th Annual Meeting of the American Society for the Study of Liver Disease currently taking place in Boston. Just in case you couldn’t attend, or haven’t checked out the abstracts, let me be the first to inform you that folks got pretty excited about a previously little-known compound being tested by Gilead with the exotic name GS-9190. It's a polymerase inhibitor therapy for hepatitis C that suddenly shows a lot of promise.   Read More...

  Discuss ( 2 comments) 60,263 Views Digg this | Email this | Link to this